Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Summit Therapeutics plc
SMMT | US
22.08
USD-0.19
-0.85%
SMMT | US
Loading StockChartView...
About Summit Therapeutics plc
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
30/06/2024
As of date
24/04/2026
Close
22.08
Open
22.28
High
22.36
Low
21.45
Summit Therapeutics Inc. a biopharmaceutical company research and develops primarily oncology therapies in the United States and the United Kingdom. The company's product pipeline includes SMT-738 a novel class of precision antibiotics for treatment which is in preclinical stage for the treatment of multidrug resistant infections which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso Inc. for research and develop Ivonescimab (AK112) and SMT112 a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis. The company was founded in 2003 and is headquartered in Cambridge Massachusetts.
View LessSMMT | US
Risk
99.0
Sharpe
-0.44
Luna's Score
33/100
Recommendation
Sell
Luna says (SMMT | US)
What's Working
Largecap (10B - 200B USD)
What's not Working
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Low negative Beta, possible Low Liquidity (< -0.4)
Rich in Valuation (Price to Book > 8)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
102.5%1 month
99.0%3 months
71.7%6 months
65.6%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
81.26
Debt to equity
0.56
Debt to assets
0.32
Ent. to EBITDA
-5.32
Ent. to rev.
6.43K
PEG
-
Other Fundamentals
EBITDA
-143.59M
MarketCap
16.23B
MarketCap(USD)
16.23B
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-102.77
Short ratio
1.53
Short perc.
14.06
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
10.08
Range1M
13.39
Range3M
15.40
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.35
Price X volume
115.12M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -5.32 | 24.85 | Cheaper |
| Ent. to Revenue | 6,425.28 | 361.91 | Expensive |
| PE Ratio | - | 30.05 | - |
| Price to Book | 81.26 | 13.15 | Expensive |
| Dividend Yield | - | 2.94 | - |
| Std. Deviation (3M) | 71.73 | 65.24 | Par |
| Debt to Equity | 0.56 | -1.88 | Expensive |
| Debt to Assets | 0.32 | 0.48 | Cheaper |
| Market Cap | 16.23B | 3.71B | Market Leader |
